
Russell William Jenkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/531254/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018, 175, 998-1013.e20.	28.9	1,260
2	Mechanisms of resistance to immune checkpoint inhibitors. British Journal of Cancer, 2018, 118, 9-16.	6.4	944
3	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24.	28.9	892
4	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	9.4	503
5	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	9.4	392
6	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine, 2018, 24, 1143-1150.	30.7	212
7	Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology, 2021, 141, 23-31.	0.7	193
8	3D microfluidic <i>ex vivo</i> culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab on A Chip, 2018, 18, 3129-3143.	6.0	185
9	Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Communications Biology, 2021, 4, 122.	4.4	139
10	Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clinical Lung Cancer, 2015, 16, e101-e104.	2.6	85
11	Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54.	6.7	83
12	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunology Research, 2016, 4, 520-530.	3.4	79
13	Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discovery, 2022, 12, 812-835.	9.4	55
14	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clinical Cancer Research, 2018, 24, 4854-4864.	7.0	49
15	Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Systems, 2017, 5, 105-118.e9.	6.2	40
16	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Annual Review of Medicine, 2018, 69, 333-347.	12.2	38
17	Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. Journal of Clinical Investigation, 2021, 131, .	8.2	35
18	Targeting TANK-binding kinase 1 (TBK1) in cancer. Expert Opinion on Therapeutic Targets, 2020, 24, 1065-1078	3.4	26

#	Article	IF	CITATIONS
19	Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2013, 88, E265-72.	4.1	19
20	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. Cancers, 2021, 13, 6052.	3.7	15
21	<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma management. Melanoma Management, 2016, 3, 47-59.	0.5	12
22	Refining Targeted Therapy Opportunities for <i>BRAF</i> -Mutant Melanoma. Cancer Discovery, 2017, 7, 799-801.	9.4	4
23	861â€Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy. , 2021, 9, A902-A902.		1